SS i : Safety stock of the ith supplier's item.
The reason for that is two-fold: (i) safety of the athletes and (ii) reduction of equipment impact on competition outcome.
Four important criteria (i) Safety, (ii) Cost, (iii) Value Added, (iv) Execution Capability, and subsequently eleven sub-criteria (section "Maintenance strategy attributes and alternatives") have been considered for maintenance decision making for system under study.
Magnetic nanoparticle (MNP -based vector systeMNP -basedn, offer a combination of key benefits for cell therapies including (i) safety (ii) delivectorf therapeutic biomoleculesystemssinNA) enhanceable by 'magneturnctiofferpproacombinationmagnetic cell targeting of MNP-labelled cells to injury sites and (iv) non-invasive imaging of MNP-labelled transplant populations for cell trackeyg.
The results not only demonstrate the validity of the model, but also indicate that the proposed method can be applied to: i) safety evaluation of build-up intersections; ii) dangerous position management within an intersection; iii) safety assessment of designed intersections, and iv) safety level comparison among different intersections or various designs for a single intersection.
It carries out three essential functions: (i) safety, intended as compliance with ITER requirements toward public and workers protection; (ii) system control, intended as compliance with ITER operational requirements and investment protection; and (iii) scientific mission, intended as validating technology and predictive tools for blanket concepts relevant to fusion energy systems.
(i) Safety plan information for women and their children, in the form of flyers or brochures containing important numbers and addresses they could reach in case of emergency.
The feasibility of PA counseling was evaluated with four components: i) safety, ii) participant responsiveness, iii) realization of counseling and iv) applicability.
The secondary end points were as follows: (i) safety and toxicity assessed according to the National Cancer Institute Common Toxicity Criteria (version 3.0); (ii) response rates at 3, 6 and 9 months; (iii) overall survival and (iv) median time to progression.
Mr Doblin explains that since the FDA insists that psychedelics should be treated like any other drug, "we had to start with a Phase I safety study, where the drug is first used on humans even though millions of people had taken MDMA by then".
Domain I: Safety of care IHS International Headache Society.
